• letlifehappen's Avatar

    letlifehappen posted a blog post

    Source: The Reis Group From: eurekalert.org National survey finds oncologists underestimate patient use of complementary and lifestyle therapies Nearly three-quarters of breast cancer patients (73%) report using at least one type of complementary medicine after cancer diagnosis, while oncologists believe that less than half (43%) of patients are using these approaches during cancer care. These and other findings from a ...
    The post Breast cancer patients embrace integrative health during treatment appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Courtney Marabella From: onclive.com Olaparib demonstrated clinically meaningful benefit 1 year after standard of care therapies, such as surgery, chemotherapy, hormone therapy, or radiation therapy, in patients with BRCA1/2-mutant, early HER2-negative breast cancer who are at a high risk for recurrence. Olaparib (Lynparza) demonstrated clinically meaningful benefit 1 year after standard of care therapies, such as surgery, chemotherapy, hormone ...
    The post Olaparib Provides Meaningful Benefit 1 Year After Standard of Care Therapies in BRCA1/2+, High-Risk, Early HER2- Breast Cancer appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Jennifer Larson From: cancertherapyadvisor.com Pretreatment patient-reported outcomes (PROs) are potential prognostic tools for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) advanced breast cancer who are undergoing treatment with abemaciclib, a CDK4/6 inhibitor, according to a team of researchers based in Australia. Their findings were published in The Oncologist. The researchers developed a model based on data ...
    The post Patient-Reported Outcomes Predictive of PFS in Patients Receiving Abemaciclib for Advanced Breast Cancer appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    From: prweb.com Lifelink Systems today announced that its conversational technology platform is live, powering a digital FAQ chatbot on Cancer.Net, the patient information website of the American Society of Clinical Oncology (ASCO®). The medical information technology solution provides doctor-approved information about breast cancer for patients, caregivers, and health care professionals. ASCO represents nearly 45,000 oncology professionals who care for people ...
    The post Digital Assistant powered by Lifelink Systems deployed, providing on-demand breast cancer education for patients appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    Source: Novartis Pharmaceuticals Corporation From: prnewswire.com MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to the OS benefit demonstrated for premenopausal women as shown in MONALEESA-7(1,2) The relative risk reduction of death by 36% in the MONALEESA-3 first-line (1L) postmenopausal population highlights ...
    The post Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    Source: Wake Forest Baptist Medical Center From: eurekalert.org When people think of microbiome, they typically think about the gut, but there’s also a breast microbiome, and the role it plays in breast health and breast cancer isn’t thoroughly understood. A microbiome is the collection of microorganisms that live in a particular environment in the body. In 2018, scientists at Wake ...
    The post Researchers find evidence that diet can alter the microbiome to affect breast cancer risk appeared first on Let Life Happen.